Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology

Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Kucharz, Eugeniusz J., Stajszczyk, Marcin, Kotulska-Kucharz, Anna, Batko, Bogdan, Brzosko, Marek, Jeka, Sławomir, Leszczyński, Piotr, Majdan, Maria, Olesińska, Marzena, Samborski, Włodzimierz, Wiland, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2018
Materias:
Recommendations for Diagnosis and Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142023/
https://www.ncbi.nlm.nih.gov/pubmed/30237624
http://dx.doi.org/10.5114/reum.2018.77971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142023/
https://www.ncbi.nlm.nih.gov/pubmed/30237624
http://dx.doi.org/10.5114/reum.2018.77971

Ejemplares similares